Dr. James Lee on Overcoming Mismatched Repair in Colorectal Cancer

James J. Lee, MD, PhD, Assistant Professor of Medicine, Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, discusses mismatched repair in colorectal cancer.

About 5% to 10% of metastatic colorectal cancers carry a very unique mutation known as mismatched repair, says Lee.

Colorectal cancer patients that have mismatched repair have a higher chance of their cancer growing and spreading.

Pembrolizumab has the potential to activate the immune system and overcome mismatched repair, says Lee.